Biography
Edgar Marcelino de Carvalho Filho was born in Salvador, Bahia, on May 24, 1950. His parents, Edgar Marcelino de Carvalho and Valdemira Silva de Carvalho, were teachers, had teaching activities and were an example and a stimulus for the son. The secondary course was held at the Colégio AplicÃo of the Federal University of Bahia, one of the best schools in Salvador and recognized as a teacher of student leaders. The interest in medicine and teaching comes from childhood and adolescence and interest in research during the medical course at the Faculty of Medicine of the Federal University of Bahia. APSA graduation in 1973 made residence and Masters in Internal Medicine and in 1977 held fellowship in the area of Immunology and Rheumatology at the University of Virginia. The Master's thesis entitled "Patients with Bacteremia in severe strongyloidase The importance of the worm as a vehicle or synergistic agent of bacterial infection" was guided by Professor Heonir Rocha, a researcher who also directed several scientific works At the beginning of the career. The training in Immunology at the University of Virginia was conducted with Dr. David Horowitz, having been useful in relation to the learning of immunology techniques as a proficiency in scientific productivity stay. In this period they were published three manuscripts in J. Immunol. and in Clin. Exp. Immunol. . Immunology did not yet exist in Bahia when he returned in 1979, when he created the Research Laboratory in Immunology, which later was elevated to the category of Immunology Service. It was at this time that interest in leishmaniasis began, which together with schistosomiasis and strongyloidase constitute the main lines of research of the Immunology Service. He defended his doctorate in 1986 with the thesis "Cellular Immunity in Visceral Leishmaniasis", on which occasion he became an Adjunct Professor of the Faculty of Medicine of the Federal University of Bahia. He coordinated for four years the P s-Graduation course in Internal Medicine of the Federal University of Bahia and coordinates until the moment (2002) the activities of masters and doctorate in the area of Clinical Immunology. J directed 17 master's theses and 8 doctoral theses and at the moment 2 master's degrees and 7 doctoral students are under his guidance. The main lines of research are the Immunology of Visceral and Intestinal Leishmaniasis, Immunotherapy in Infectious Diseases, Immunoregulation in Mansonic Schistosomiasis and Clinical and Immunological Aspects of the Association between HTLV-1 and Strongyloidase. J was a member of the editorial board of the Brazilian Journal of Medicine and Biological Research and Associate Editor of the Journal of the Brazilian Society of Tropical Medicine. member of the Brazilian Society of Immunology, organ presided between 1989 and 1991, the American Association of immunologists , the Brazilian Society of Tropical Medicine and the American Journal of Tropical Medicine and Hygiene .
Research Interest
Immunology of tegumentary leishmaniasis. Clinical and therapeutic aspects of tegumentary leishmaniasis. Natural history and immune response in HTLV-1 infection. Association between HTLV-1 infection and helminthiasis. Immunomodulation in schistosomiasis.
Huixiao Hong
National Center for Toxicological Research (NCTR), US Food and Drug Administration (FDA)
USA
Biography
Dr. Huixiao Hong is a senior Scientist at National Center for Toxicological Research (NCTR), US Food and Drug Administration (FDA), working on the scientific bases for regulatory application and development of genomics biomarkers. Before joining the FDA, he was the Manager of Bioinformatics Division at Z-Tech, an ICFI company, at NCTR. He held a Research Scientist position at Sumitomo Chemical Company in Japan. He was a visiting scientist at National Cancer Institute (NCI) at National Institutes of Health (NIH). He was also an Associated Professor and the Director of Laboratory of Computational Chemistry at Nanjing University in China. He published more than 160 scientific papers and served as Editor-in-Chief, Executive Editor and Editorial Board member for more than 10 peer-reviewed journals and as reviewer for more than 50 scientific journals. He received his Ph.D. from Nanjing University in China in 1990 and did post-doctoral research at Maxwell Institute in Leeds University in England in 1990-1992.
Research Interest
.
Biography
Harold C. Smith, Ph.D. is a cell and molecular biologist and tenured full professor in the Department of Biochemistry and Biophysics at the University of Rochester, School of Medicine and Dentistry. As a member of the faculty, Dr. Smith developed and instructs the primary technical training course for undergraduates in the Biochemistry major and runs a research laboratory from which over 130 pier reviewed publications have emerged on biological control mechanisms affecting diseases such as cancer, elevated cholesterol and heart disease and HIV/AIDS. He has led his research field with federal and foundation funding and is a key opinion leader on APOBEC host defense factors. In 2003, Dr. Smith founded OyaGen, Inc based on ground breaking research revealing our innate ability to ward off an infection by HIV for the purpose of developing a novel drug intervention strategy towards an eventual cure for AIDS. His biotech company has unique technology and equipment that has enabled recognition of the Company by Federal, State and the pharmaceutical industry as having taken innovation to a new level with promising achievements that are of great importance and potential to the healthcare industry. OyaGen is located at 77 Ridgeland Rd in Henrietta NY, USA. For more information on Dr. Smith and OyaGen please visit the following webpages: http://en.wikipedia.org/wiki/Harold_Smith_(scientist) http://www.oyageninc.com
Research Interest
Dr. Smith founded OyaGen, Inc based on ground breaking research revealing our innate ability to ward off an infection by HIV for the purpose of developing a novel drug intervention strategy towards an eventual cure for AIDS. His biotech company has unique technology and equipment that has enabled recognition of the Company by Federal, State and the pharmaceutical industry as having taken innovation to a new level with promising achievements that are of great importance and potential to the healthcare industry.
